Broad protection from SARS-CoV-2 variants without antigen matching
- PMID: 37716366
- DOI: 10.1016/S2213-2600(23)00290-4
Broad protection from SARS-CoV-2 variants without antigen matching
Conflict of interest statement
I have received research grants from the Medical Research Future Fund (Australian Government), the Coalition for Epidemic Preparedness and Innovation, and Queensland Government; research donations from the Paul Ramsay Foundation, The Lott, and a2 Milk Company; contract research support and consulting fees (as a scientific advisor) from ViceBio Pty; and have patents granted and pending on the Molecular Clamp vaccine platform.
Comment on
-
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial.Lancet Respir Med. 2023 Nov;11(11):975-990. doi: 10.1016/S2213-2600(23)00263-1. Epub 2023 Sep 13. Lancet Respir Med. 2023. PMID: 37716365 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous